GlassScriptPhysician profile
Kaitlin L Plummer
NPI 1114378148
$17,200.43
in general payments reported to CMS, 2019-2025
50 companies · $4,080 in 2025
The $4,080 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $752 · 2020: $1,113 · 2021: $2,707 · 2022: $2,603 · 2023: $2,953 · 2024: $2,992 · 2025: $4,080.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,025.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,985.15 | 2020-2025 | |
| Novo Nordisk INC | $1,968.44 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $1,862.08 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $1,654.54 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,538.65 | 2019-2025 | Jardiance, Synjardy, Stiolto Respimat |
| Lilly USA, LLC | $1,278.95 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $680.11 | 2021-2025 | |
| Amgen INC. | $632.15 | 2019-2025 | Evenity, Prolia |
| Pfizer INC. | $578.06 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $383.22 | 2019-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $374.46 | 2019-2024 | Xarelto |
| Exact Sciences Corporation | $324.38 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $293.50 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $278.14 | 2019-2025 | Vaxelis, Vaxneuvance, Gardasil 9 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $223.83 | 2025 | Caplyta |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $214.91 | 2022-2025 | Eliquis, Camzyos |
| Astellas Pharma US INC | $205.46 | 2020-2025 | Veozah, Myrbetriq |
| Biohaven Pharmaceutical Holding Company LTD. | $195.75 | 2022 | |
| Dexcom, INC. | $194.92 | 2022-2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $173.20 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $165.56 | 2021-2022 | |
| Abbott Laboratories | $150.66 | 2021-2025 | Freestyle Libre 3 |
| Sanofi Pasteur INC. | $144.98 | 2020-2024 | |
| Allergan, INC. | $140.13 | 2020 | |
| Shield Therapeutics INC | $136.38 | 2023-2025 | Accrufer |
| Axsome Therapeutics, INC. | $120.06 | 2024-2025 | Symbravo, Auvelity |
| Ibsa Pharma INC. | $118.57 | 2019-2025 | Tirosint, Licart, Flector |
| Novartis Pharmaceuticals Corporation | $118.54 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $115.24 | 2019-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $101.10 | 2020-2025 | Rexulti |
| Corcept Therapeutics | $97.09 | 2024-2025 | Korlym |
| Verona Pharma, INC. | $77.82 | 2025 | Ohtuvayre |
| Phathom Pharmaceuticals, INC. | $72.47 | 2024-2025 | Voquezna |
| Vanda Pharmaceuticals INC. | $60.54 | 2025 | Fanapt |
| Genentech USA, INC. | $60.35 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $56.67 | 2020-2022 | |
| Tactile Systems Technology INC | $55.36 | 2021-2023 | Entre Plus, Flexitouch Plus |
| Sanofi-Aventis U.S. LLC | $51.94 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $51.36 | 2025 | Gemtesa |
| Actelion Pharmaceuticals US, INC. | $38.30 | 2025 | Opsynvi, Uptravi |
| Philips North America LLC | $32.86 | 2022 | |
| Xeris Pharmaceuticals, INC. | $31.68 | 2025 | Gvoke Hypopen |
| Seqirus USA INC | $25.45 | 2025 | Flucelvax, Fluad |
| Inspire Medical Systems, INC. | $23.91 | 2024 | Inspire |
| Phadia US INC. | $23.72 | 2025 | Immunocap |
| Esperion Therapeutics, INC. | $21.88 | 2025 | Nexletol |
| Viatris Specialty LLC | $19.34 | 2025 | Yupelri |
| Ars Pharmaceuticals Operations, INC. | $18.37 | 2025 | Neffy |
| Alnylam Pharmaceuticals INC. | $15.74 | 2023 | Givlaari |
| Alkermes, INC. | $14.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaitlin Plummer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.